FDA Clearance Tracker · P990027-S021
TECHNOLAS TENEO 317 (MODEL 2) Excimer Laser System
Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Nov 22, 2023
Approved
Time to decision
293 days
Received Feb 2, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P990027-S021
- Device name
- TECHNOLAS TENEO 317 (MODEL 2) Excimer Laser System
- Applicant
- Technolas Perfect Vision GmbH
- Applicant location
- MüNchen
- Received
- Feb 2, 2023
- Decided
- Nov 22, 2023
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P990027
Device type
- Device type
- Excimer laser system (LZS)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for the TECHNOLAS TENEO 317 MODEL 2 Excimer Laser System. This device is indicated for laser-assisted in situ keratomileusis (LASIK) in: Patients for the reduction or elimination of myopic astigmatism up to -10.00 D MRSE, with sphere between -1.00 D to -10.0 D and cylinder between 0.00 and -3.00 D; Patients who are 22 years of age or older; Patients must have a stable refraction in the last 12 months, as documented by previous clinical recordings, i.e., the spherical and cylindrical portions of the manifest distance refraction have not progressed at a rate of more than 0.50 D per year prior to the baseline examination in the eye(s) to be treated.
Source documents
Other decisions for Technolas Perfect Vision GmbH
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K200724 · Decided Sep 1, 2020 · 166 days after receipt
Device type: Ophthalmic Femtosecond Laser (OOE) · Ophthalmology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.